Investment demonstrates value of RSE Enterprise Fellowship scheme
A company formed during an RSE Enterprise Fellowship funded by the BBSRC has today announced the receipt of £2m from investment led by Epidarex Capital, an international early-stage life science venture capital fund.
Clyde Biosciences Ltd. was formed by company CEO Dr Margaret Anne Craig in 2012 and spun out of Glasgow University’s College of Medical Veterinary and Life Sciences.
The new investment milestone marks the latest of the Scottish company’s successes as it works to develop drug toxicity solutions for the pharmaceutical and biotechnology markets.
The news demonstrates the great potential offered by the RSE Enterprise Fellowships scheme, and comes as the Society is inviting applications for its next cohort of Enterprise Fellows.
Commenting, Dr. Craig said, “Since its inception, Clyde Biosciences has been working hard to meet our clients’ needs in improving outcomes in drug development. This investment, led by Epidarex Capital, will help propel Clyde Biosciences to a new level, allowing us to strengthen our team, reinforce our commercial offering and broaden our geographic reach. We welcome the support of our investment partners and look forward to an exciting future.”
View Dr Craig discussing her Fellowship experience in the video below